US20030093114A1 - Method for effecting hemostasis - Google Patents
Method for effecting hemostasis Download PDFInfo
- Publication number
- US20030093114A1 US20030093114A1 US10/008,052 US805201A US2003093114A1 US 20030093114 A1 US20030093114 A1 US 20030093114A1 US 805201 A US805201 A US 805201A US 2003093114 A1 US2003093114 A1 US 2003093114A1
- Authority
- US
- United States
- Prior art keywords
- glucosamine
- poly
- biopolymer
- closure pad
- puncture wound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 67
- 230000023597 hemostasis Effects 0.000 title claims abstract description 16
- 206010052428 Wound Diseases 0.000 claims abstract description 55
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims abstract description 27
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229920001222 biopolymer Polymers 0.000 claims abstract description 27
- 229960002442 glucosamine Drugs 0.000 claims abstract description 27
- 125000002091 cationic group Chemical group 0.000 claims abstract description 9
- 239000012530 fluid Substances 0.000 claims abstract description 4
- 238000003825 pressing Methods 0.000 claims abstract description 4
- 229920001661 Chitosan Polymers 0.000 claims description 27
- 159000000021 acetate salts Chemical class 0.000 claims description 21
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 19
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 18
- 239000000835 fiber Substances 0.000 claims description 17
- 208000027418 Wounds and injury Diseases 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 210000004204 blood vessel Anatomy 0.000 claims description 7
- 238000012795 verification Methods 0.000 claims description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 208000032843 Hemorrhage Diseases 0.000 description 9
- 230000000740 bleeding effect Effects 0.000 description 9
- 210000001367 artery Anatomy 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 229920002101 Chitin Polymers 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 206010018852 Haematoma Diseases 0.000 description 4
- 235000011121 sodium hydroxide Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 241000233866 Fungi Species 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 230000006196 deacetylation Effects 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 241000238421 Arthropoda Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 239000004775 Tyvek Substances 0.000 description 1
- 229920000690 Tyvek Polymers 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- -1 lactic acid Chemical class 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000002910 solid waste Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00365—Plasters use
- A61F2013/00412—Plasters use for use with needles, tubes or catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00365—Plasters use
- A61F2013/00463—Plasters use haemostatic
- A61F2013/00472—Plasters use haemostatic with chemical means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Definitions
- the present invention relates to a method for local management of bleeding wounds and, more particularly, a method for rapidly controlling bleeding even in patients receiving hemodialysis and anticoagulation treatments.
- the nurse or physician will create an opening into an artery or other vessel with a conventional catheter introducer or dilator. Additionally, the catheter is often twisted or otherwise manipulated as it is advanced to the treatment site, thereby causing a further enlargement of the incision or puncture in the body of the patient.
- What is desired therefore is a simple, safe and relatively inexpensive method for managing bleeding wounds such as lacerations, abrasions, nose bleeds, vascular access sites, percutaneous catherters, or tubes and surgical debridement.
- the method will provide a rapid control of bleeding even in patients receiving hemodialysis and anticoagulation treatments.
- the present invention provides a method for effecting hemostasis at a puncture wound extending to a blood vessel.
- the puncture wound may, or may not, have an introducer or catheter disposed therein.
- the method includes applying pressure proximal to the puncture wound, and directing a cationic application surface of a closure pad against the puncture wound with force sufficient to prevent fluid from exiting the puncture wound, by collapsing the blood vessel.
- the pressure proximal to the puncture wound is then removed. If an introducer or catheter is present, it is then removed from the puncture wound.
- the method then includes maintaining the force on the closure pad against the wound for at least a first predetermined time period. Upon verification (usually visually) of hemostasis, the force to the pad is removed.
- Dressing may be applied over the closure pad and the puncture wound. The dressing and the closure pad will then be removed after a second predetermined time period.
- the application surface of the pad is a biopolymer of glucosamine, including but not limited to poly-N-acetylglucosamine.
- the application surface is an acetate salt of a biopolymer of glucosamine.
- the first predetermined time period is substantially proportional to the diameter of the introducer or the catheter.
- the first predetermined time period is equal to about ten minutes.
- the second predetermined time period is equal to about twenty-four hours.
- the method of the present invention provides many benefits, including reducing the time period required to stop bleeding at a puncture wound and decreasing the likelihood that a hematoma will form particularly, but not limited to, cases following removal of an introducer or a catheter from the puncture wound.
- FIG. 1 is a side elevation view, partially in section, showing a catheter extending through a puncture wound into an artery of a patient, with the puncture wound extending through an epidermal and dermal layer of the patient's skin and through a wall of the artery;
- FIG. 2 is a side elevation view, partially in section, showing the catheter removed from the puncture wound and a closure pad secured to the patient's skin over the puncture wound in accordance with a method of the present invention for effecting hemostasis;
- FIG. 3 is a side elevation view, partially in section, showing the closure pad secured to the patient's skin over the puncture wound in accordance with the present invention, and hemostasis occurring within the puncture wound;
- FIG. 4 is a flow chart illustrating the method of the present invention for effecting hemostasis in a puncture wound.
- the present invention is described hereinafter with specific reference to the use of the present invention for sealing an incision or puncture wound leading to a blood vessel in a patient. It is contemplated that the present invention may be used with nearly any catheterization or other medical procedure such as laparoscopic or other minimally or less invasive surgeries wherein it is desirable to seal an incision or puncture wound in the patient to prevent the loss of the patient's body fluid therethrough.
- FIGS. 1 through 3 a brief description of a conventional angiographic catheterization procedure through a femoral artery 10 of a patient is set forth herein and illustrated in FIGS. 1 through 3, for purposes of illustration.
- an angiographic needle (not shown) is inserted percutaneously through the epidermal and dermal layer of the skin 12 of the patient at an angle to form an incision or puncture wound 14 .
- the needle is inserted percutaneously into the skin 12 until the needle pierces the wall of the femoral artery 10 .
- the puncture of the artery 10 by the needle is then confirmed by the physician and a small diameter guide wire (not shown) is inserted through a central lumen in the needle and the needle is withdrawn over the guide wire while pressure is applied to the artery 10 to limit the bleeding and prevent the formation of a hematoma at the incision site.
- the catheter 16 and an outer introducer or catheter sheath are inserted over the guide wire.
- the catheter 16 is advanced to the final location and the procedure is performed. Once the procedure has been completed, the catheter 16 is removed and a method according to the present invention for controlling bleeding from the puncture wound 14 is conducted as described hereinafter.
- the method includes applying pressure proximal to the puncture wound 14 to at least partially collapse the blood vessel 10 , as shown at “A”, and directing a cationic biopolymer of glucosamine application surface of a closure pad 18 against the puncture wound 14 with force sufficient to substantially prevent fluid from exiting the puncture wound 14 , as shown at “B”. Then the pressure proximal to the puncture wound 14 is removed, as shown at “C”, and the catheter 16 is removed from the puncture wound 14 , as shown at “D”.
- the method then includes maintaining the force on the closure pad 18 and against the wound 14 for at least a first predetermined time period, as shown at “E”, and removing the force on the closure pad, as shown at “G”, if hemostasis is verified, as shown at “F”. Hemostasis is generally verified visually.
- a dressing (not shown), can also be applied over the closure pad 18 and the puncture wound 14 , as shown at “H”.
- the dressing and the closure pad 18 are then removed after a second predetermined time period, as shown at “I”.
- the application surface of, and in some forms of the invention, the entire closure pad 18 are preferably made substantially only of a cationic biopolymer of glucosamine provided in one or more of the following forms: poly-D-glucosamine; an acetate salt of poly-N-acetylglucosamine; an acetate salt of poly-D-glucosamine; poly-N-acetylglucosamine and poly-D-glucosamine; an acetate salt of poly-N-acetylglucosamine and poly-D-glucosamine; an acetate salt of poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine; and poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.
- the application surface is water soluble. Acidic environments other than an acetate salt, such as lactic acid, can also be incorporated
- a cationic biopolymer of glucosamine is derived from chitosan, which is a collective term applied to deacetylated chitins in various stages of deacetylation and depolymerization.
- Chitin is the structural polymer of the exo-skeleton of arthropods and cell walls of fungi, and is composed of poly-N-Acetyl glucosamine units. These are linked by Beta 1-4 glycosidic bonds into a linear polymer containing 2,000 to 3,000 units.
- Chitosan is a derivative of solid waste from shell fish processing and can be extracted from fungus culture.
- Chitin is generally isolated and purified by first dissolving away the inorganic material, calcium carbonate, by treatment with hydrochloric acid. After the protein material is removed by digestion with hot diluted alkali, the chitin is bleached with permanganate followed by treatment with oxalic acid. Partial deacetylization of chitin by treatment with concentrated alkali solution at 130 to 150 degrees centigrade yields products which are soluble in dilute acetic acid.
- a common method to convert crab shell to Chitosan is as follows: The calcium carbonate is removed by immersing the shell in cold dilute hydrochloric acid, two to three hours are allowed for the reaction. The shell is then thoroughly rinsed with water. Protein is removed by treating the shell with caustic soda (3% strength). The shell is cooked in a 3% sodium hydroxide solution for a period of two hours at a temperature of 100° C. and at atmospheric pressure. The remains are rinsed thoroughly with water to remove all traces of sodium hydroxide and protein, and bleached with potassium permanganate solution and again rinsed with water.
- the remains are then treated with oxalic acid to remove the permanganate solution, and then treated with a 40% caustic soda solution at 150° C. to partially deacetylate the chitosan.
- various viscosities of chitosan can be produced.
- the final pH of the chitosan solution is in the range of 4-5. It is possible to utilize chitosan in the following applications in various pH's and viscosities.
- the ideal mode is a solution of 2 grams of chitosan per liter of acetic acid solution. This process is discussed in U.S. Pat. No. 4,394,373 to Malette et al., which is incorporated herein by reference.
- the remainder of the closure pad 18 can be made of a material that supports and/or supplements the application surface.
- the remainder of the closure pad 18 can, for example, comprise absorbent or non-absorbent material, and a rigid, semi-rigid or soft material.
- the remainder of the closure pad 18 can, for example, comprise a plastic, a cellulose polymer, or other suitable material.
- the application surface of, and in some forms of the invention, the entire closure pad 18 is soft and made of non-woven fibers.
- the application surface and/or the entire closure pad 18 can be made of woven material, layers of woven material, and woven and non-woven layers.
- the closure pad 18 Prior to use, the closure pad 18 is packed in a pouch (for example, made of foil, paper or Tyvek® material) and sterilized (for example, by E-beam radiation, ethylene oxide, or other suitable sterilization method, to a 10 ⁇ 6 sterility assurance level).
- a pouch for example, made of foil, paper or Tyvek® material
- sterilized for example, by E-beam radiation, ethylene oxide, or other suitable sterilization method, to a 10 ⁇ 6 sterility assurance level.
- the first predetermined time period is substantially proportional to a diameter of the catheter 16 (or of a diameter of an introducer for the catheter, if the introducer is used), and thus the resulting puncture wound 14 .
- the first predetermined time period is preferably equal to about ten minutes, although other time periods can be used.
- the pressure is not removed from the closure pad 18 and the puncture wound 14 until hemostasis is confirmed. Thus force may need to be maintained on the closure pad 18 for longer than ten minutes.
- the dressing can comprise gauze pads and tape, or other suitable dressings, placed over the closure pad.
- the second predetermined time period is preferably equal to about twenty-four hours. After twenty-four hours, the dressing and the closure pad 18 are removed from the puncture wound. If hemostasis can not be confirmed after removal of the dressing and the closure pad, a new closure pad and dressing should be applied to the wound, until hemostasis is confirmed.
- the method of the present invention provides many benefits, including reducing the time period required to stop bleeding at a puncture wound and decreasing the likelihood that a hematoma will form after removal of a catheter from the puncture wound. Modification to above-described preferred embodiment of the presently disclosed invention may become apparent to those skilled in the art. The scope of the invention is therefore intended to be limited solely by the scope of the appended claims.
Abstract
A method for effecting hemostasis at a puncture wound, includes applying pressure proximal to the puncture wound, and directing a cationic biopolymer of glucosamine application surface of a closure pad against the puncture wound with force sufficient to prevent fluid from exiting the puncture wound. Then the pressure proximal to the puncture wound is removed and the force on the closure pad is maintained for at least a first predetermined time period. The force on the closure pad is removed if hemostasis is verified. The puncture wound may then be dressed over the closure pad, and the dressing and the closure pad removed after a second predetermined time period.
Description
- The present invention relates to a method for local management of bleeding wounds and, more particularly, a method for rapidly controlling bleeding even in patients receiving hemodialysis and anticoagulation treatments.
- During catheterization procedures, the nurse or physician will create an opening into an artery or other vessel with a conventional catheter introducer or dilator. Additionally, the catheter is often twisted or otherwise manipulated as it is advanced to the treatment site, thereby causing a further enlargement of the incision or puncture in the body of the patient.
- When the medical procedure is completed and the catheter is removed from the artery or other blood vessel, conventional practice has been to apply external pressure to the entry site until hemostasis occurs. Because many of the patients undergoing these procedures have been medicated with an anticoagulant such as heparin, the nurse may be required to apply external pressure to the incision site for an extended period of time period. The time period required to stop bleeding at the incision is not an efficient use of the nurses time period and a painful hematoma or unsightly bruise may still occur at the incision site because the artery will continue to bleed internally until clotting blocks the opening in the artery.
- What is desired therefore is a simple, safe and relatively inexpensive method for managing bleeding wounds such as lacerations, abrasions, nose bleeds, vascular access sites, percutaneous catherters, or tubes and surgical debridement. Preferably, the method will provide a rapid control of bleeding even in patients receiving hemodialysis and anticoagulation treatments.
- The present invention provides a method for effecting hemostasis at a puncture wound extending to a blood vessel. The puncture wound may, or may not, have an introducer or catheter disposed therein. The method includes applying pressure proximal to the puncture wound, and directing a cationic application surface of a closure pad against the puncture wound with force sufficient to prevent fluid from exiting the puncture wound, by collapsing the blood vessel. The pressure proximal to the puncture wound is then removed. If an introducer or catheter is present, it is then removed from the puncture wound. The method then includes maintaining the force on the closure pad against the wound for at least a first predetermined time period. Upon verification (usually visually) of hemostasis, the force to the pad is removed. Dressing may be applied over the closure pad and the puncture wound. The dressing and the closure pad will then be removed after a second predetermined time period.
- According to one aspect of the present invention, the application surface of the pad is a biopolymer of glucosamine, including but not limited to poly-N-acetylglucosamine. In some forms of the invention, the application surface is an acetate salt of a biopolymer of glucosamine.
- According to further aspect of the present invention, when an introducer or catheter is disposed in the wound, the first predetermined time period is substantially proportional to the diameter of the introducer or the catheter. According to another aspect, the first predetermined time period is equal to about ten minutes. According to an additional aspect, the second predetermined time period is equal to about twenty-four hours.
- The method of the present invention provides many benefits, including reducing the time period required to stop bleeding at a puncture wound and decreasing the likelihood that a hematoma will form particularly, but not limited to, cases following removal of an introducer or a catheter from the puncture wound. These and other features and benefits of the present disclosure will become more apparent upon reading the following specification in combination with the accompanying drawing figures.
- FIG. 1 is a side elevation view, partially in section, showing a catheter extending through a puncture wound into an artery of a patient, with the puncture wound extending through an epidermal and dermal layer of the patient's skin and through a wall of the artery;
- FIG. 2 is a side elevation view, partially in section, showing the catheter removed from the puncture wound and a closure pad secured to the patient's skin over the puncture wound in accordance with a method of the present invention for effecting hemostasis;
- FIG. 3 is a side elevation view, partially in section, showing the closure pad secured to the patient's skin over the puncture wound in accordance with the present invention, and hemostasis occurring within the puncture wound; and
- FIG. 4 is a flow chart illustrating the method of the present invention for effecting hemostasis in a puncture wound.
- Like reference characters designate identical or corresponding components and units throughout the several views.
- The present invention is described hereinafter with specific reference to the use of the present invention for sealing an incision or puncture wound leading to a blood vessel in a patient. It is contemplated that the present invention may be used with nearly any catheterization or other medical procedure such as laparoscopic or other minimally or less invasive surgeries wherein it is desirable to seal an incision or puncture wound in the patient to prevent the loss of the patient's body fluid therethrough.
- In order to more fully understand and appreciate the present invention, a brief description of a conventional angiographic catheterization procedure through a
femoral artery 10 of a patient is set forth herein and illustrated in FIGS. 1 through 3, for purposes of illustration. In such a procedure, an angiographic needle (not shown) is inserted percutaneously through the epidermal and dermal layer of theskin 12 of the patient at an angle to form an incision orpuncture wound 14. The needle is inserted percutaneously into theskin 12 until the needle pierces the wall of thefemoral artery 10. The puncture of theartery 10 by the needle is then confirmed by the physician and a small diameter guide wire (not shown) is inserted through a central lumen in the needle and the needle is withdrawn over the guide wire while pressure is applied to theartery 10 to limit the bleeding and prevent the formation of a hematoma at the incision site. Thecatheter 16 and an outer introducer or catheter sheath (not shown) are inserted over the guide wire. Next, thecatheter 16 is advanced to the final location and the procedure is performed. Once the procedure has been completed, thecatheter 16 is removed and a method according to the present invention for controlling bleeding from thepuncture wound 14 is conducted as described hereinafter. - Referring also to FIG. 4, the method includes applying pressure proximal to the
puncture wound 14 to at least partially collapse theblood vessel 10, as shown at “A”, and directing a cationic biopolymer of glucosamine application surface of aclosure pad 18 against thepuncture wound 14 with force sufficient to substantially prevent fluid from exiting thepuncture wound 14, as shown at “B”. Then the pressure proximal to thepuncture wound 14 is removed, as shown at “C”, and thecatheter 16 is removed from thepuncture wound 14, as shown at “D”. The method then includes maintaining the force on theclosure pad 18 and against thewound 14 for at least a first predetermined time period, as shown at “E”, and removing the force on the closure pad, as shown at “G”, if hemostasis is verified, as shown at “F”. Hemostasis is generally verified visually. - A dressing (not shown), can also be applied over the
closure pad 18 and thepuncture wound 14, as shown at “H”. The dressing and theclosure pad 18 are then removed after a second predetermined time period, as shown at “I”. - Preferably, the application surface of, and in some forms of the invention, the
entire closure pad 18, are preferably made substantially only of a cationic biopolymer of glucosamine provided in one or more of the following forms: poly-D-glucosamine; an acetate salt of poly-N-acetylglucosamine; an acetate salt of poly-D-glucosamine; poly-N-acetylglucosamine and poly-D-glucosamine; an acetate salt of poly-N-acetylglucosamine and poly-D-glucosamine; an acetate salt of poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine; and poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine. In forms including an acetate salt, the application surface is water soluble. Acidic environments other than an acetate salt, such as lactic acid, can also be incorporated as part of the biopolymer of glucosamine. - A cationic biopolymer of glucosamine is derived from chitosan, which is a collective term applied to deacetylated chitins in various stages of deacetylation and depolymerization. Chitin is the structural polymer of the exo-skeleton of arthropods and cell walls of fungi, and is composed of poly-N-Acetyl glucosamine units. These are linked by Beta 1-4 glycosidic bonds into a linear polymer containing 2,000 to 3,000 units.
- Chitosan is a derivative of solid waste from shell fish processing and can be extracted from fungus culture. Chitin is generally isolated and purified by first dissolving away the inorganic material, calcium carbonate, by treatment with hydrochloric acid. After the protein material is removed by digestion with hot diluted alkali, the chitin is bleached with permanganate followed by treatment with oxalic acid. Partial deacetylization of chitin by treatment with concentrated alkali solution at 130 to 150 degrees centigrade yields products which are soluble in dilute acetic acid.
- A common method to convert crab shell to Chitosan, for example, is as follows: The calcium carbonate is removed by immersing the shell in cold dilute hydrochloric acid, two to three hours are allowed for the reaction. The shell is then thoroughly rinsed with water. Protein is removed by treating the shell with caustic soda (3% strength). The shell is cooked in a 3% sodium hydroxide solution for a period of two hours at a temperature of 100° C. and at atmospheric pressure. The remains are rinsed thoroughly with water to remove all traces of sodium hydroxide and protein, and bleached with potassium permanganate solution and again rinsed with water. The remains are then treated with oxalic acid to remove the permanganate solution, and then treated with a 40% caustic soda solution at 150° C. to partially deacetylate the chitosan. This results in the formation of chitosan. By varying the amount of deacetylation, various viscosities of chitosan can be produced. The final pH of the chitosan solution is in the range of 4-5. It is possible to utilize chitosan in the following applications in various pH's and viscosities. However, the ideal mode is a solution of 2 grams of chitosan per liter of acetic acid solution. This process is discussed in U.S. Pat. No. 4,394,373 to Malette et al., which is incorporated herein by reference.
- If only the application surface of the
closure pad 18 is made of a cationic biopolymer of glucosamine, then the remainder of theclosure pad 18 can be made of a material that supports and/or supplements the application surface. The remainder of theclosure pad 18 can, for example, comprise absorbent or non-absorbent material, and a rigid, semi-rigid or soft material. The remainder of theclosure pad 18 can, for example, comprise a plastic, a cellulose polymer, or other suitable material. - In addition, the application surface of, and in some forms of the invention, the
entire closure pad 18, is soft and made of non-woven fibers. However, the application surface and/or theentire closure pad 18, can be made of woven material, layers of woven material, and woven and non-woven layers. - Prior to use, the
closure pad 18 is packed in a pouch (for example, made of foil, paper or Tyvek® material) and sterilized (for example, by E-beam radiation, ethylene oxide, or other suitable sterilization method, to a 10−6 sterility assurance level). - The first predetermined time period is substantially proportional to a diameter of the catheter16 (or of a diameter of an introducer for the catheter, if the introducer is used), and thus the resulting puncture wound 14. In general, however, the first predetermined time period is preferably equal to about ten minutes, although other time periods can be used. In any event, the pressure is not removed from the
closure pad 18 and the puncture wound 14 until hemostasis is confirmed. Thus force may need to be maintained on theclosure pad 18 for longer than ten minutes. The dressing can comprise gauze pads and tape, or other suitable dressings, placed over the closure pad. - The second predetermined time period is preferably equal to about twenty-four hours. After twenty-four hours, the dressing and the
closure pad 18 are removed from the puncture wound. If hemostasis can not be confirmed after removal of the dressing and the closure pad, a new closure pad and dressing should be applied to the wound, until hemostasis is confirmed. - The method of the present invention provides many benefits, including reducing the time period required to stop bleeding at a puncture wound and decreasing the likelihood that a hematoma will form after removal of a catheter from the puncture wound. Modification to above-described preferred embodiment of the presently disclosed invention may become apparent to those skilled in the art. The scope of the invention is therefore intended to be limited solely by the scope of the appended claims.
Claims (40)
1. A method for effecting hemostasis at a puncture wound extending to a blood vessel, comprising:
A) applying pressure proximal to the puncture wound in order to at least partially collapse the blood vessel;
B) directing an application surface of a closure pad against the puncture wound with force sufficient to substantially prevent fluid from exiting the puncture wound, wherein the application surface is a cationic biopolymer of glucosamine;
C) removing the pressure proximal to the puncture wound;
D) maintaining the force on the closure pad against the puncture wound for at least a first predetermined time period;
E) removing the force on the closure pad upon verification of hemostasis.
2. The method of claim 1 , wherein the entire closure pad including the application surface comprises a cationic biopolymer of glucosamine.
3. The method of claim 2 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine.
4. The method of claim 3 , wherein the closure pad is made of non-woven fibers.
5. The method of claim 2 , wherein the biopolymer of glucosamine is poly-D-glucosamine.
6. The method of claim 5 , wherein the closure pad is made of non-woven fibers.
7. The method of claim 2 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine.
8. The method of claim 7 , wherein the closure pad is made of non-woven fibers.
9. The method of claim 2 , wherein the biopolymer of glucosamine is an acetate salt of poly-D-glucosamine.
10. The method of claim 9 , wherein the closure pad is made of non-woven fibers.
11. The method of claim 2 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and poly-D-glucosamine.
12. The method of claim 11 , wherein the closure pad is made of non-woven fibers.
13. The method of claim 2 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and poly-D-glucosamine.
14. The method of claim 13 , wherein the closure pad is made of non-woven fibers.
15. The method of claim 1 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.
16. The method of claim 15 , wherein the closure pad is made of non-woven fibers.
17. The method of claim 2 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.
18. The method of claim 17 , wherein the closure pad is made of non-woven fibers.
19. The method of claim 2 , wherein the application surface comprises a cationic biopolymer of glucosamine and a remainder of the closure pad comprises another material.
20. The method of claim 19 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine.
21. The method of claim 20 , wherein the application surface is made of non-woven fibers.
22. The method of claim 19 , wherein the biopolymer of glucosamine is poly-D-glucosamine.
23. The method of claim 22 , wherein the application surface is made of non-woven fibers.
24. The method of claim 19 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine.
25. The method of claim 24 , wherein the application surface is made of non-woven fibers.
26. The method of claim 19 , wherein the biopolymer of glucosamine is an acetate salt of poly-D-glucosamine.
27. The method of claim 26 , wherein the application surface is made of non-woven fibers.
28. The method of claim 19 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and poly-D-glucosamine.
29. The method of claim 28 , wherein the application surface is made of non-woven fibers.
30. The method of claim 19 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and poly-D-glucosamine.
31. The method of claim 30 , wherein the application surface is made of non-woven fibers.
32. The method of claim 19 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.
33. The method of claim 32 , wherein the application surface is made of non-woven fibers.
34. The method of claim 19 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.
35. The method of claim 34 , wherein the application surface is made of non-woven fibers.
36. The method of claim 1 , wherein the first predetermined time period is equal to about ten minutes.
37. The method of claim 1 , wherein an introducer having an outer diameter is disposed in the puncture wound and removed from the wound prior to removing the pressure proximal to the wound, and wherein the first predetermined time period is substantially proportional to the diameter of the introducer.
38. The method of claim 1 , further comprising:
applying a dressing over the closure pad and the puncture wound; and
removing the dressing and the closure pad from the puncture wound after a second predetermined time period.
39. The method of claim 38 , wherein the second predetermined time period is equal to about twenty-four hours.
40. The method of claim 38 , wherein the dressing includes gauze.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/008,052 US20030093114A1 (en) | 2001-11-13 | 2001-11-13 | Method for effecting hemostasis |
US10/267,940 US20030153528A1 (en) | 2001-11-13 | 2002-10-09 | Hemostatic bone wax composition |
US10/267,902 US20030148994A1 (en) | 2001-11-13 | 2002-10-09 | Hemostatic composition |
US10/286,614 US6638296B2 (en) | 2001-11-13 | 2002-11-01 | Hemostasis pad and method |
US10/286,566 US6890344B2 (en) | 2001-11-13 | 2002-11-01 | Hemostasis pad and method |
AU2002363798A AU2002363798A1 (en) | 2001-11-13 | 2002-11-13 | Method for effecting hemostasis |
PCT/US2002/036564 WO2003041564A2 (en) | 2001-11-13 | 2002-11-13 | Method for effecting hemostasis |
US11/125,765 US20050222615A1 (en) | 2001-11-13 | 2005-05-10 | Hemostasis pad and method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/008,052 US20030093114A1 (en) | 2001-11-13 | 2001-11-13 | Method for effecting hemostasis |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/267,940 Continuation-In-Part US20030153528A1 (en) | 2001-11-13 | 2002-10-09 | Hemostatic bone wax composition |
US10/267,902 Continuation-In-Part US20030148994A1 (en) | 2001-11-13 | 2002-10-09 | Hemostatic composition |
US10/286,566 Continuation-In-Part US6890344B2 (en) | 2001-11-13 | 2002-11-01 | Hemostasis pad and method |
US10/286,614 Continuation-In-Part US6638296B2 (en) | 2001-11-13 | 2002-11-01 | Hemostasis pad and method |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030093114A1 true US20030093114A1 (en) | 2003-05-15 |
Family
ID=21729584
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/008,052 Pending US20030093114A1 (en) | 2001-11-13 | 2001-11-13 | Method for effecting hemostasis |
US10/267,902 Abandoned US20030148994A1 (en) | 2001-11-13 | 2002-10-09 | Hemostatic composition |
US10/267,940 Abandoned US20030153528A1 (en) | 2001-11-13 | 2002-10-09 | Hemostatic bone wax composition |
US10/286,614 Expired - Lifetime US6638296B2 (en) | 2001-11-13 | 2002-11-01 | Hemostasis pad and method |
US10/286,566 Expired - Lifetime US6890344B2 (en) | 2001-11-13 | 2002-11-01 | Hemostasis pad and method |
US11/125,765 Abandoned US20050222615A1 (en) | 2001-11-13 | 2005-05-10 | Hemostasis pad and method |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/267,902 Abandoned US20030148994A1 (en) | 2001-11-13 | 2002-10-09 | Hemostatic composition |
US10/267,940 Abandoned US20030153528A1 (en) | 2001-11-13 | 2002-10-09 | Hemostatic bone wax composition |
US10/286,614 Expired - Lifetime US6638296B2 (en) | 2001-11-13 | 2002-11-01 | Hemostasis pad and method |
US10/286,566 Expired - Lifetime US6890344B2 (en) | 2001-11-13 | 2002-11-01 | Hemostasis pad and method |
US11/125,765 Abandoned US20050222615A1 (en) | 2001-11-13 | 2005-05-10 | Hemostasis pad and method |
Country Status (3)
Country | Link |
---|---|
US (6) | US20030093114A1 (en) |
AU (1) | AU2002363798A1 (en) |
WO (1) | WO2003041564A2 (en) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6998510B2 (en) * | 2002-02-04 | 2006-02-14 | Damage Control Surgical Technologies, Inc. | Method and apparatus for improved hemostasis and damage control operations |
AU2003294238A1 (en) * | 2002-10-30 | 2004-06-07 | Joel S. Rossen | Simplified one-handed preemptive medical procedure site dressing to prevent sharps injuries and exposure to bloodborne pathogens |
US7943810B2 (en) | 2003-02-04 | 2011-05-17 | Buckman Robert F | Method and apparatus for hemostasis |
CN102579162A (en) * | 2003-09-23 | 2012-07-18 | 奥索康公司 | Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects |
US7955616B2 (en) * | 2003-09-23 | 2011-06-07 | Orthocon, Inc. | Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects |
US20050267520A1 (en) | 2004-05-12 | 2005-12-01 | Modesitt D B | Access and closure device and method |
US7678133B2 (en) | 2004-07-10 | 2010-03-16 | Arstasis, Inc. | Biological tissue closure device and method |
US7622628B2 (en) * | 2005-05-04 | 2009-11-24 | Innovasa Corporation | Hemostatic wire guided bandage and method of use |
US20060276836A1 (en) * | 2005-06-07 | 2006-12-07 | Bergin Patrick J | Hemostatic wire guided bandage and method of use |
US20080015481A1 (en) * | 2005-05-04 | 2008-01-17 | Bergin Patrick J | Hemostatic bandage and method of use |
US20060276838A1 (en) * | 2005-06-07 | 2006-12-07 | Wensel Jeffrey P | Vascular puncture sealing method, apparatus, and system |
AU2006247355B2 (en) | 2005-05-12 | 2013-01-10 | Arstasis, Inc. | Access and closure device and method |
US20080269659A1 (en) * | 2005-06-07 | 2008-10-30 | Bergin Patrick J | Hemostatic Bandage |
US20070122361A1 (en) * | 2005-11-29 | 2007-05-31 | Weitao Jia | Tooth colorant and whitener, method of manufacture, and method of use thereof |
US20070154509A1 (en) * | 2005-12-30 | 2007-07-05 | Wilcher Steve A | Adsorbent-Containing Hemostatic Devices |
US20070154510A1 (en) * | 2005-12-30 | 2007-07-05 | Wilcher Steve A | Adsorbent-Containing Hemostatic Devices |
US8277837B2 (en) | 2006-01-11 | 2012-10-02 | Entegrion, Inc. | Hemostatic textile |
US7905852B2 (en) | 2006-05-16 | 2011-03-15 | Barbara Jennings-Spring | Skin-contacting-adhesive free dressing |
US7645252B2 (en) | 2006-05-16 | 2010-01-12 | Barbara Brooke Jennings-Spring | Body or plant part dressing |
US20090287133A1 (en) * | 2006-06-06 | 2009-11-19 | Lagreca Sr Alfred J | Disposable or Reclosable Wound or Skin Condition Dressing and Treatment System |
US20080097270A1 (en) * | 2006-08-25 | 2008-04-24 | Utterberg David S | Resilient hemostasis devices |
US20080063697A1 (en) * | 2006-09-08 | 2008-03-13 | Bedard Robert L | Use of Unactivated Calcium Exchanged Zeolites in Hemostatic Devices and Products |
US8623842B2 (en) * | 2006-09-27 | 2014-01-07 | Hemostasis, Llc | Hemostatic agent and method |
US8100937B2 (en) | 2006-10-10 | 2012-01-24 | Smalling Medical Ventures, Llc | Pressure assist system for facilitating vascular hemostasis, and associated method |
US7931651B2 (en) * | 2006-11-17 | 2011-04-26 | Wake Lake University Health Sciences | External fixation assembly and method of use |
US20080145455A1 (en) * | 2006-12-13 | 2008-06-19 | Bedard Robert L | Combination of Inorganic Hemostatic Agents with Other Hemostatic Agents |
US9066885B2 (en) * | 2007-03-16 | 2015-06-30 | University Of Maryland, College Park | Advanced functional biocompatible polymeric matrix containing nano-compartments |
US8932560B2 (en) | 2007-09-04 | 2015-01-13 | University of Maryland, College Parke | Advanced functional biocompatible polymeric matrix used as a hemostatic agent and system for damaged tissues and cells |
US8597253B2 (en) | 2007-04-20 | 2013-12-03 | Bard Access Systems | Huber needle with safety sheath |
US20090047366A1 (en) * | 2007-08-15 | 2009-02-19 | Bedard Robert L | Inorganic Coagulation Accelerators for Individuals taking Platelet Blockers or Anticoagulants |
US8883194B2 (en) * | 2007-11-09 | 2014-11-11 | Honeywell International, Inc. | Adsorbent-containing hemostatic devices |
US8795718B2 (en) * | 2008-05-22 | 2014-08-05 | Honeywell International, Inc. | Functional nano-layered hemostatic material/device |
CN102159139A (en) | 2008-07-18 | 2011-08-17 | 韦克福里斯特大学健康科学院 | Apparatus and method for cardiac tissue modulation by topical application of vacuum to minimize cell death and damage |
CN102159126A (en) | 2008-07-21 | 2011-08-17 | 阿尔斯塔西斯公司 | Devices, methods, and kits for forming tracts in tissue |
US20110112572A1 (en) * | 2009-11-10 | 2011-05-12 | Tyco Healthcare Group Lp | Hemostatic Tapes and Dispensers Therefor |
US20110108199A1 (en) * | 2009-11-10 | 2011-05-12 | Tyco Healthcare Group Lp | Hemostatic Tapes and Dispensers Therefor |
EP2498820B1 (en) | 2009-11-13 | 2019-01-09 | University of Maryland, College Park | Advanced functional biocompatible foam used as a hemostatic agent for compressible and non-compressible acute wounds |
CN101862469B (en) * | 2010-05-28 | 2013-03-13 | 武汉人福医疗用品有限公司 | Chitosan derivative quick hemostasis granules and preparation method thereof |
US8302323B2 (en) | 2010-06-21 | 2012-11-06 | Confluent Surgical, Inc. | Hemostatic patch |
CA2819186C (en) * | 2010-07-14 | 2018-06-19 | Bard Access Systems, Inc. | A dressing device for use with a cannula or a catheter |
US8664199B2 (en) | 2010-08-13 | 2014-03-04 | University Of Maryland, College Park | Method and system for reversal of interactions between hydrophobically modified biopolymers and vesicles or cell membranes |
US20140066894A1 (en) | 2010-09-10 | 2014-03-06 | C. R. Bard, Inc. | Self-Sealing Pad for a Needle-Based Infusion Set |
US10525234B2 (en) | 2010-09-10 | 2020-01-07 | C. R. Bard, Inc. | Antimicrobial/haemostatic interface pad for placement between percutaneously placed medical device and patient skin |
CA2806393A1 (en) | 2010-09-10 | 2012-03-15 | C.R. Bard, Inc. | Systems for isolation of a needle-based infusion set |
US9427360B2 (en) | 2010-11-04 | 2016-08-30 | W. Jerry Mezger | Hemostatic fabric |
WO2012075457A2 (en) | 2010-12-02 | 2012-06-07 | University Of Maryland, College Park | Method and system for capture and use of intact vesicles on electrodeposited hydrophobically modified biopolymer films |
WO2013048787A1 (en) | 2011-09-26 | 2013-04-04 | Yes, Inc. | Novel hemostatic compositions and dressings for bleeding |
US20130317481A1 (en) | 2012-05-25 | 2013-11-28 | Arstasis, Inc. | Vascular access configuration |
US20130317438A1 (en) | 2012-05-25 | 2013-11-28 | Arstasis, Inc. | Vascular access configuration |
US8658193B2 (en) * | 2012-06-08 | 2014-02-25 | Robert J. Greenwald | Styptic storage and delivery |
US8889655B2 (en) | 2012-07-20 | 2014-11-18 | Aegis Women's Health Technologies | Compositions and methods for preventing infectious diseases in females |
US8969649B2 (en) * | 2012-08-10 | 2015-03-03 | Ethicon, Inc. | Integrated dressing device |
WO2014137824A1 (en) * | 2013-03-07 | 2014-09-12 | Life Sciences Llc | Apparatus & method for wound infection prevention |
CA2914610C (en) | 2013-03-13 | 2022-08-02 | University Of Maryland | Advanced functional biocompatible polymer putty used as a hemostatic agent for treating damaged tissue and cells |
US8961479B2 (en) | 2013-03-19 | 2015-02-24 | Biolife, L.L.C. | Hemostatic device and method |
US20150057640A1 (en) * | 2013-08-22 | 2015-02-26 | Evelyn M. Tarkington | Circular bandage for drain tube |
US10195399B2 (en) | 2013-10-29 | 2019-02-05 | Avent, Inc. | Catheter securement device |
US9764116B2 (en) | 2013-12-30 | 2017-09-19 | Avent, Inc. | Catheter insertion site plug |
WO2015103423A1 (en) | 2013-12-31 | 2015-07-09 | Confluence Llc | Medical devices, dressings, and methods for closing openings in tissue |
US10406255B2 (en) | 2014-05-28 | 2019-09-10 | Highland Industries, Inc. | Hemostatic textile |
US11627795B2 (en) | 2017-02-14 | 2023-04-18 | G-Tech Llc | Shoulder transfer weight support system and face shield |
CN111954499B (en) * | 2018-05-16 | 2023-09-22 | 泰尔茂株式会社 | Compression apparatus |
CN110538024B (en) * | 2019-09-03 | 2022-06-14 | 重庆市渝北区人民医院 | Portable medical pressurizing application device, use method and application |
WO2021134005A1 (en) * | 2019-12-27 | 2021-07-01 | Hg Medical Technologies Llc | Iontophoretic wound treatment device |
US11272941B1 (en) | 2020-08-07 | 2022-03-15 | William P Buchanan | Secondary device holder and compression system, method of making and using the same |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3632754A (en) * | 1968-02-12 | 1972-01-04 | Lescarden Ltd | Use of chitin for promoting wound healing |
US4059097A (en) * | 1976-11-03 | 1977-11-22 | American Cyanamid Company | Method of minimizing tissue reaction during surgery with chitin |
US4394373A (en) * | 1981-04-06 | 1983-07-19 | Malette William Graham | Method of achieving hemostasis |
US4981133A (en) * | 1989-10-10 | 1991-01-01 | Rollband Ernest J | Pressure bandage for puncture wounds with a target marketing |
US5203764A (en) * | 1985-10-04 | 1993-04-20 | Minnesota Mining And Manufacturing Company | Foam pads useful in wound management |
US5269803A (en) * | 1992-04-10 | 1993-12-14 | Gtr Patent, Inc. | Hemostasis pressure pad band |
US5310402A (en) * | 1990-12-03 | 1994-05-10 | Rollband Ernest J | Temporary bandage tape |
US5324252A (en) * | 1991-03-25 | 1994-06-28 | Minnesota Mining And Manufacturing Company | Foam pads useful in wound management |
US5336219A (en) * | 1993-03-23 | 1994-08-09 | Medi-Flex Hospital Products, Inc. | Skin closure system |
US5486195A (en) * | 1993-07-26 | 1996-01-23 | Myers; Gene | Method and apparatus for arteriotomy closure |
US5510102A (en) * | 1995-01-23 | 1996-04-23 | The Regents Of The University Of California | Plasma and polymer containing surgical hemostatic adhesives |
US5665107A (en) * | 1993-09-28 | 1997-09-09 | Hemodynamics, Inc. | Surface opening adhesive sealer |
US5985434A (en) * | 1997-11-25 | 1999-11-16 | Kimberly-Clark Worldwide, Inc. | Absorbent foam |
US6060461A (en) * | 1999-02-08 | 2000-05-09 | Drake; James Franklin | Topically applied clotting material |
US20010001316A1 (en) * | 1997-12-17 | 2001-05-17 | Closys Corporation | Clotting cascade initiating apparatus and methods of use and methods of closing wounds |
US6234989B1 (en) * | 1995-06-07 | 2001-05-22 | Gambro, Inc. | Extracorporeal blood processing methods and apparatus |
US20020015724A1 (en) * | 1998-08-10 | 2002-02-07 | Chunlin Yang | Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing |
US20020062104A1 (en) * | 1999-09-23 | 2002-05-23 | Mark Ashby | Depth and puncture control for blood vessel hemostasis system |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1027501B (en) * | 1968-12-06 | 1978-12-20 | Muzzarelli Weckx M G F | CHITIN CHITOSAN AND DERIVATIVES USED AS CHROMATOGRAPHIC SUPPORTS AND AS ADSORBENTS FOR THE COLLECTION OF IONS FROM WATER AND ORGANIC SOLUTIONS FROM DRINKING AND SEA WATER |
US3969189A (en) * | 1971-12-14 | 1976-07-13 | Kumiai Chemical Industry Co., Ltd. | Cell wall-lysing complex enzymes and a process for the production thereof |
US3811438A (en) | 1972-03-30 | 1974-05-21 | G Economou | Adhesive tapes and bandages |
US4532134A (en) * | 1981-04-06 | 1985-07-30 | Malette William Graham | Method of achieving hemostasis, inhibiting fibroplasia, and promoting tissue regeneration in a tissue wound |
US4833238A (en) * | 1986-12-16 | 1989-05-23 | E. I. Du Pont De Nemours And Company | High strength fibers from chitin derivatives |
FR2616318A1 (en) * | 1987-06-15 | 1988-12-16 | Centre Nat Rech Scient | ARTIFICIAL SKIN AND PROCESS FOR PREPARING THE SAME |
US4784653A (en) * | 1987-06-22 | 1988-11-15 | Johnson & Johnson Patient Care, Inc. | Absorbent adhesive dressing |
US5086764A (en) * | 1989-04-13 | 1992-02-11 | Thomas Gilman | Absorbent dressing |
US5429591A (en) * | 1991-07-22 | 1995-07-04 | Nitto Denko Corporation | Absorbent dressing having backing and continuous adhesive layer |
US5375588A (en) * | 1992-08-17 | 1994-12-27 | Yoon; Inbae | Method and apparatus for use in endoscopic procedures |
US5683354A (en) * | 1993-07-06 | 1997-11-04 | Levy; Raymond H. | Adhesive bandage for a digit of a human hand or foot |
US5714543A (en) * | 1994-01-13 | 1998-02-03 | Bristol-Myers Squibb Company | Water soluble polymer additives for polyurethane-based pressure sensitive adhesives |
US5533962A (en) * | 1995-05-12 | 1996-07-09 | Peterman; Shadi | Ringless adhesive bandage |
US5836970A (en) | 1996-08-02 | 1998-11-17 | The Kendall Company | Hemostatic wound dressing |
US5807341A (en) * | 1996-12-11 | 1998-09-15 | Team Medical Llc | Medical catheter dressing device |
US6596699B2 (en) * | 1998-09-22 | 2003-07-22 | Biosurface Engineering Technologies, Inc. | Nucleic acid coating compositions and methods |
ES2269069T3 (en) | 1999-06-08 | 2007-04-01 | Ethicon, Inc. | WOVEN SURGICAL MESH. |
US6586651B2 (en) * | 1999-11-01 | 2003-07-01 | John Patrick Sullivan | Adhensive bandage with soft, three-dimensional toy |
US7012169B2 (en) * | 2000-04-06 | 2006-03-14 | Kimberly-Clark Worldwide, Inc. | Disposable finger sleeve for appendages |
US6316686B1 (en) * | 2000-06-20 | 2001-11-13 | Timothy N. Byrd | Medical pressure dressing and process |
-
2001
- 2001-11-13 US US10/008,052 patent/US20030093114A1/en active Pending
-
2002
- 2002-10-09 US US10/267,902 patent/US20030148994A1/en not_active Abandoned
- 2002-10-09 US US10/267,940 patent/US20030153528A1/en not_active Abandoned
- 2002-11-01 US US10/286,614 patent/US6638296B2/en not_active Expired - Lifetime
- 2002-11-01 US US10/286,566 patent/US6890344B2/en not_active Expired - Lifetime
- 2002-11-13 WO PCT/US2002/036564 patent/WO2003041564A2/en not_active Application Discontinuation
- 2002-11-13 AU AU2002363798A patent/AU2002363798A1/en not_active Abandoned
-
2005
- 2005-05-10 US US11/125,765 patent/US20050222615A1/en not_active Abandoned
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3632754A (en) * | 1968-02-12 | 1972-01-04 | Lescarden Ltd | Use of chitin for promoting wound healing |
US4059097A (en) * | 1976-11-03 | 1977-11-22 | American Cyanamid Company | Method of minimizing tissue reaction during surgery with chitin |
US4394373A (en) * | 1981-04-06 | 1983-07-19 | Malette William Graham | Method of achieving hemostasis |
US5203764A (en) * | 1985-10-04 | 1993-04-20 | Minnesota Mining And Manufacturing Company | Foam pads useful in wound management |
US4981133A (en) * | 1989-10-10 | 1991-01-01 | Rollband Ernest J | Pressure bandage for puncture wounds with a target marketing |
US5310402A (en) * | 1990-12-03 | 1994-05-10 | Rollband Ernest J | Temporary bandage tape |
US5324252A (en) * | 1991-03-25 | 1994-06-28 | Minnesota Mining And Manufacturing Company | Foam pads useful in wound management |
US5269803A (en) * | 1992-04-10 | 1993-12-14 | Gtr Patent, Inc. | Hemostasis pressure pad band |
US5336219A (en) * | 1993-03-23 | 1994-08-09 | Medi-Flex Hospital Products, Inc. | Skin closure system |
US5486195A (en) * | 1993-07-26 | 1996-01-23 | Myers; Gene | Method and apparatus for arteriotomy closure |
US5665107A (en) * | 1993-09-28 | 1997-09-09 | Hemodynamics, Inc. | Surface opening adhesive sealer |
US5510102A (en) * | 1995-01-23 | 1996-04-23 | The Regents Of The University Of California | Plasma and polymer containing surgical hemostatic adhesives |
US6234989B1 (en) * | 1995-06-07 | 2001-05-22 | Gambro, Inc. | Extracorporeal blood processing methods and apparatus |
US5985434A (en) * | 1997-11-25 | 1999-11-16 | Kimberly-Clark Worldwide, Inc. | Absorbent foam |
US20010001316A1 (en) * | 1997-12-17 | 2001-05-17 | Closys Corporation | Clotting cascade initiating apparatus and methods of use and methods of closing wounds |
US20020015724A1 (en) * | 1998-08-10 | 2002-02-07 | Chunlin Yang | Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing |
US6060461A (en) * | 1999-02-08 | 2000-05-09 | Drake; James Franklin | Topically applied clotting material |
US20020062104A1 (en) * | 1999-09-23 | 2002-05-23 | Mark Ashby | Depth and puncture control for blood vessel hemostasis system |
Also Published As
Publication number | Publication date |
---|---|
US20030153528A1 (en) | 2003-08-14 |
AU2002363798A1 (en) | 2003-05-26 |
US6890344B2 (en) | 2005-05-10 |
US6638296B2 (en) | 2003-10-28 |
WO2003041564A2 (en) | 2003-05-22 |
US20050222615A1 (en) | 2005-10-06 |
US20030093075A1 (en) | 2003-05-15 |
US20030093115A1 (en) | 2003-05-15 |
WO2003041564A3 (en) | 2003-12-04 |
US20030148994A1 (en) | 2003-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20030093114A1 (en) | Method for effecting hemostasis | |
US5437292A (en) | Method for sealing blood vessel puncture sites | |
US20200197019A1 (en) | Temporary occlusion balloon devices, systems and methods for preventing flow through a vascular perforation | |
Hoekstra et al. | Percutaneous microcrystalline chitosan application for sealing arterial puncture sites | |
US10434212B2 (en) | Degradable haemostat composition | |
EP3003411B1 (en) | Degradable haemostat composition | |
US20060282046A1 (en) | Device and method for subcutaneous delivery of blood clotting agent | |
EP3334352A1 (en) | Temporary occlusion balloon devices and methods for preventing blood flow through a vascular perforation | |
CN114014953B (en) | Functionalized chitosan microsphere and preparation method and application thereof | |
JP6807922B2 (en) | Biocompatible carboxymethyl cellulose matrix (BCM) for hemostasis, tissue barrier, wound healing, and cosmetology | |
US20110224713A1 (en) | Slotted introducer needle and method for accessing a body lumen | |
CN106822987A (en) | A kind of porous ball hemostatic material preparation method of shitosan alginate | |
CN107412842B (en) | Preparation method of alginate wound dressing with thrombin | |
Khanna et al. | Recommendations for Treatment of Exit-Site P a Thology | |
CN109010906B (en) | Biological glue for promoting postoperative wound local hemostasis and promoting postoperative wound epithelization and working method thereof | |
US8591451B2 (en) | Surgical methods, devices, and kits | |
CN112138206A (en) | Bone hemostatic material | |
CN114269350A (en) | Topical hemostatic compositions | |
US20200000645A1 (en) | Method for reducing blood loss | |
Manea et al. | Nasal packing in endonasal surgery-a literature review | |
CN117599235A (en) | Application of Floccuronic acid polysaccharide in preparation of liquid hemostatic material for treating non-compressible hemorrhage and secondary hemorrhage | |
CN112138204A (en) | Bone hemostatic material | |
BARNETT et al. | Vascular access in the newborn | |
WO2005023333A2 (en) | Supercutaneous method and device for promoting hemostasis in cannulated patient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SCION CARDIO-VASCULAR, INC., FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEVINSON, MELVIN;GOLIK, GEORGE;MANZANO, ERNEST;AND OTHERS;REEL/FRAME:012612/0875;SIGNING DATES FROM 20011114 TO 20011115 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |